Prospective, compartment-resolved biomarker studies are needed to match agonists, delivery systems, combination regimens, or inhibitory approaches to the appropriate tumor state, and STING inhibition in chromosomal-instability-high tumors remains a promising preclinical hypothesis, not an established treatment.